Novartis CYTB323K12201; CAR-T for Scleroderma
Internal Medicine
Skin and Dermatologic
Adult Subjects
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.